234 Church Street
About Biohaven Pharma
223 articles with Biohaven Pharma
Portage Biotech is pleased to announce that it has completed the distribution of shares of Biohaven Pharma to all eligible Portage shareholders.
Biohaven Announces Initiation of Clinical Development for BHV-5000, a Novel Low-Trapping NMDA Antagonist
Enrollment of subjects has started for the IND opening study, which will test single and multiple doses of a solid-dose formulation of BHV-5000 in healthy volunteers.
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet
Biohaven announced positive results today from its bioequivalence study with BHV-0223, an innovative sublingual formulation of riluzole.
12/21/2017Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Biohaven Enrolls First Patient in Pivotal Trial of Trigriluzole in Patients With Obsessive-Compulsive Disorder
Biohaven today announced that it has commenced enrollment in its Phase 2/3 clinical trial assessing the efficacy and safety of trigriluzole in patients with OCD.
Biohaven Completes Enrollment in Second Pivotal Phase III Clinical Trial of Oral CGRP-Receptor Antagonist Rimegepant
The trial began shortly after the commencement of rimegepant's first efficacy trial, Study BHV3000-301, and the two trials enrolled simultaneously with the objective of announcing topline results for the migraine program in the first quarter of 2018.
Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine
Agreement on an iPSP is one of the regulatory requirements that must be met prior to submitting a NDA.
Biohaven Completes Enrollment in the First of Two Pivotal Phase III Clinical Trials of Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist, for the Acute Treatment of Migraine
Biohaven Pharma announced that it is completing enrollment today in the first of its two registrational Phase III clinical trials, Study BHV3000-301, to establish the safety and efficacy of orally-dosed rimegepant.
Biohaven Pharma today reported financial results for the quarter ended September 30, 2017, and provided a review of recent accomplishments and anticipated upcoming milestones.
Mr. Phillips will focus on further advancing Biohaven's infrastructure to support the Company's accounting, external reporting and finance capabilities.
Portage Biotech plans to distribute as stock dividend, a substantial part of the 6,341,500 common shares it holds in Biohaven Pharma.
Biohaven is developing BHV-0223, a sublingual formulation of riluzole, as a potential treatment for patients with ALS.
Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of sublingual BHV-0223 as a potential treatment for patients with ALS.
Biohaven Announces First Patient Treated in Clinical Research Collaboration At Rutgers Cancer Institute
Biohaven announced a clinical collaboration today with Drs. Ann Silk and James Goydos at the Rutgers Cancer Institute of New Jersey.
Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced the appointment of Clifford Bechtold as the company's first COO.
Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder
Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of trigriluzole, a novel glutamate modulator, as a potential treatment for patients with OCD.
Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase II Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease
Biohaven Completes Randomization In Phase II/III Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017